By Heather Blumenthal Aly-Khan Lalani is excited. He’s very excited, with terms like innovative and first in the world spilling out as he speaks. And it’s all about a clinical trial of Cytoreductive Stereotactic Hypofractionated Radiotherapy with Combination Ipilimumab and Nivolumab, or CYTOSHRINK. Which sounds, frankly, a bit technical – and makes it a… Read more »
Category: News
Where Are They Now: Andrea Vervoort
At BioCanRx, we are incredibly proud of our HQP and their dedication to cancer immunotherapy research. Whether they are working on viruses in the lab or examining the socioeconomic barriers to adopting certain treatments in Canada, each one plays a unique role in strengthening our network and expertise in immunotherapy. BioCanRx is invested in… Read more »
Successful Virtual Summit for Cancer Immunotherapy
In late November, BioCanRx’s network community, stakeholders and sponsors met virtually for the fifth Summit for Cancer Immunotherapy (Summit4CI) – BioCanRx’s annual scientific conference. Summit4CI brought together close to 400 attendees including leading scientists, clinicians, trainees, economists and representatives from industry, patient groups, charities and government. The Scientific Programming Committee organized a great… Read more »
Evening the odds for health-system coverage of costly immunotherapies
By Heather Blumenthal In the current calculus of healthcare funders, new treatments like CAR-T therapy often fail to get approval at the provincial reimbursement stage with cost playing a significant role in that failure. A BioCanRx-funded study is trying to enhance the likelihood that these therapies will be covered. Here’s how it generally… Read more »
The HQP Experience at Summit4CI
We’ve recently concluded the fifth annual Summit for Cancer Immunotherapy (Summit4CI)! Although we were virtual it was wonderful to gather as a network. The conference this year was an immense success and provided a learning and networking opportunity for undergraduate and graduate students, post-doctoral fellows, faculty, and technical staff. HQP Development Day As… Read more »
A multi-target improvement for CAR T therapy
By Heather Blumenthal Llamas have served the people of the Andes mountains in South America for centuries, as pack animals and sources of fibre and food. Today, llamas are also being put to work here in Canada, to help develop novel forms of antibodies that can then be used for CAR T therapy. … Read more »
Where Are They Now: Hayley McKay
At BioCanRx, we are incredibly proud of our HQP and their dedication to cancer immunotherapy research. Whether they are working on viruses in the lab or examining the socioeconomic barriers to adopting certain treatments in Canada, each one plays a unique role in strengthening our network and expertise in immunotherapy. BioCanRx is invested in… Read more »
CAR T-cell therapy: Canadian patient in landmark trial shares his story
A CAR T-cell therapy clinical trial, led by Dr. Natasha Kekre, of The Ottawa Hospital and BioCanRx network investigator, transformed an Ottawa man’s life. The Ontario Institute for Cancer Research and BC Cancer are also partners on this important trial. Thirty days after receiving CAR T-cell therapy treatment, “the Lymphoma was gone.” Watch his… Read more »
BioCanRx Summer Students Tell All
Another summer has already come and gone, and that means that the 17 undergraduate students who embarked on a BioCanRx-funded research internship in cancer immunotherapeutics have also taken their leave. We are so proud of the way our summer students have learned and developed, and we want to extend our best wishes to them for… Read more »
Where Are They Now: Rob Mould
At BioCanRx, we are incredibly proud of our HQP and their dedication to cancer immunotherapy research. Whether they are working on viruses in the lab or examining the socioeconomic barriers to adopting certain treatments in Canada, each one plays a unique role in strengthening our network and expertise in immunotherapy. BioCanRx is invested in… Read more »
